secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2026-09-29T20:06:24+00:00
Accession:  0001193125-26-407330
Event type: regulatory
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cytek Biosciences board adopts amended and restated bylaws effective September 23, 2026
--------------------------------------------------------------------------------

- Board unanimously adopted amended and restated bylaws on September 23, 2026, effective immediately; Exhibit 3.1 attached to the 8-K.
- Changes include removing Rule 14a-8 prefatory clause and adding disclosure/representation requirements for stockholder proposal proponents and director nominees.
- Bylaws expand chairperson authority to disregard non-compliant nominations and incorporate Rule 14a-19 universal proxy rules; add special meeting advance notice procedures.
- Also update adjournment notices for virtual/remote meetings and stockholder list procedures under Delaware General Corporation Law; CEO Wenbin Jiang signed on September 29, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526407330/0001193125-26-407330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526407330/d94407d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-407330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer